Jin Ketao, He Kuifeng, Han Na, Li Guangliang, Wang Haohao, Xu Zhenzhen, Jiang Haiping, Zhang Jing, Teng Lisong
Department of Surgical Oncology, Zhejiang University, Zhejiang, China.
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1814-22. doi: 10.5754/hge11136. Epub 2011 Jul 15.
BACKGROUND/AIMS: Lack of appropriate tumor models that reliably predict response to anticancer agents remains a major deficiency in the clinical practice of personalized cancer therapy. The aim of our study was to establish a patient-derived tumor tissue (PDTT) xenograft model of gastric carcinoma for personalized cancer therapeutic regimen selection and testing of novel molecularly targeted agents.
Patient-derived tumor tissue of primary gastric carcinoma was used to create the xenograft model. After 11 weeks, xenografts were harvested for serial transplantation. H&E staining, immunohistochemical staining and Western blotting were used to determine biological stability of the xenograft during serial transplantation compared with the original tumor tissue. Drug sensitivities of the xenograft to bevacizumab (Avastin), FP3 and cetuximab were evaluated.
背景/目的：缺乏能够可靠预测抗癌药物反应的合适肿瘤模型仍然是个性化癌症治疗临床实践中的一个主要缺陷。我们研究的目的是建立一种用于个性化癌症治疗方案选择和新型分子靶向药物测试的胃癌患者来源肿瘤组织（PDTT）异种移植模型。
使用原发性胃癌患者来源的肿瘤组织创建异种移植模型。11周后，收获异种移植瘤用于连续传代移植。与原始肿瘤组织相比，采用苏木精-伊红（H&E）染色、免疫组织化学染色和蛋白质免疫印迹法来确定异种移植瘤在连续传代移植过程中的生物学稳定性。评估了异种移植瘤对贝伐单抗（阿瓦斯汀）、FP3和西妥昔单抗的药物敏感性。
